Today: 7 February 2026
Subscribe

Datavault AI stock jumps premarket as DVLT traders focus on Jan. 7 warrant dividend clock

Datavault AI stock jumps premarket as DVLT traders focus on Jan. 7 warrant dividend clock

Datavault AI Inc shares jumped 22.7% to $0.80 in premarket trading Friday ahead of a Jan. 7 record date for proposed warrant and token dividends. Top holder Scilex reported it still owns 42.6% after selling 20.7 million shares last week. About 274,000 shares traded premarket. Warrants will require holders to also own a Dream Bowl Meme Coin II token in a Datavault wallet.
2 January 2026
·
Bitmine stock slips in premarket as crypto-linked shares ease into 2026

Bitmine stock slips in premarket as crypto-linked shares ease into 2026

Bitmine Immersion Technologies shares fell about 2% to $27.15 in early premarket trading Friday, even as bitcoin and ether rose. Investors are watching Bitmine’s January 15 annual meeting in Las Vegas, where shareholders will vote on board seats and key proposals. The company reported holding over 4.1 million ether, 192 bitcoin, and $1 billion in cash as of December 28. Several other crypto-linked stocks also traded lower premarket.
2 January 2026
··
UK energy bills forecast to drop £138 in April 2026 after levy shake-up

UK energy bills forecast to drop £138 in April 2026 after levy shake-up

Cornwall Insight forecasts the UK energy price cap will drop 8% in April, lowering a typical annual dual-fuel bill to about £1,620. Ofgem’s cap for Jan.–Mar. rose 0.2% to £1,758, driven by higher policy and supplier costs. The April cut is linked to budget changes moving some levies to general taxation. Wholesale prices have eased, but some network charges are still set to rise.
2 January 2026
·
IREN stock rises in premarket as bitcoin rebounds — what traders are watching

IREN stock rises in premarket as bitcoin rebounds — what traders are watching

IREN Limited shares rose 3.1% to $38.95 in premarket trading Friday, tracking bitcoin’s 1.6% climb to $89,034. The stock, valued at $10.9 billion, traded between $37.20 and $39.03 in the previous session. Other U.S.-listed miners were mixed. Traders are watching bitcoin’s $90,000 level and IREN’s next earnings report on Feb. 11.
2 January 2026
······
Baidu stock in focus as Kunlunxin Hong Kong listing plan lands — and Jefferies lifts target

Baidu stock in focus as Kunlunxin Hong Kong listing plan lands — and Jefferies lifts target

Baidu filed a confidential application to list its AI chip unit Kunlunxin in Hong Kong as part of a planned spin-off. Baidu’s Hong Kong shares rose 7.5% to HK$141.30, while its U.S.-listed shares last closed at $130.66, down 1.3%. The company said the deal is not finalized and would require regulatory approvals. Investors await details on deal structure and potential impact on U.S. trading.
2 January 2026
··
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 02.01.2026

Manorama Industries' stock fell 7.3% in three months despite a 30% ROE and 47% five-year net income growth, both above industry averages. DOMS Industries' shares rose 6.9% as its 19% ROE and 38% net income growth also outpaced peers. Sunpower Group delivered a 123% total return in a year, but EPS dropped 46%. Trent Limited reported a 26% ROE, beating the sector's 12%.
2 January 2026
···
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics shares closed up 3.5% at $63.54, ahead of the planned U.S. launch of Myqorzo for obstructive hypertrophic cardiomyopathy. EVP Andrew Callos sold 1,809 shares at $62.44 under a preset trading plan, retaining 51,353 shares. Investors await U.S. pricing, early prescription data, and a late February earnings update. Myqorzo carries a boxed warning and REMS safety requirements.
2 January 2026
·
AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

Axsome Therapeutics shares surged 22.9% to $182.64 on Dec. 31 after the FDA accepted its AXS-05 filing for Alzheimer’s disease agitation and set an April 30, 2026 target action date. The company also said it plans to submit an NDA for AXS-12 in narcolepsy in January, following supportive FDA meeting minutes. Trading volume reached 3.1 million shares.
2 January 2026
·
1 … 617 618 619 620 621 … 1,635

Stock Market Today

Go toTop